1887

Abstract

Purpose. There is a lack of consensus about which non-human immunodeficiency virus (HIV) patient groups would benefit from prophylaxis. Here, we analysed an enhanced Pneumocystis jirovecii database to describe the epidemiology of Pneumocystis pneumonia (PCP) and P. jirovecii colonizations in Northern Ireland (NI) with a view to identifying risk groups who may benefit from prophylaxis.

Methodology. We prospectively collected information on demographics, clinical severity and clinical features for all hospital inpatients in NI aged ≥18 years with P. jirovecii confirmed in any respiratory tract sample. We defined P. jirovecii colonization or PCP according to clinical symptoms and radiological findings. We compared P. jirovecii colonization to PCP using exact logistic regression and presented the odds ratios (OR), 95 % confidence intervals (CI) and likelihood ratio test P-values.

Results/Key findings. Overall, 36/49 (73 %) of P. jirovecii detections were categorized as PCP. A total of 28/36 (78 %) were in non-HIV patients, of which 18 (64 %) had cancer. The odds of PCP compared to P. jirovecii colonization were eight times higher in those with current exposure to chemotherapy (OR 8.73; 95 % CI 0.84, ∞), 16 times higher for those diagnosed with HIV (OR 16.2; 95 % CI 1.71, ∞) and 12 times higher for those ever exposed to another immunosuppressive drug (OR 12.1; 95 % CI 1.94, ∞).

Conclusion. The greatest burden of PCP is now in the non-HIV group, particularly cancer patients. We recommend increasing clinician awareness of PCP risk and strengthening prevention guidelines in non-HIV patients, and promoting the consideration of prophylaxis on a case-by-case basis.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000617
2017-10-17
2019-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/11/1650.html?itemId=/content/journal/jmm/10.1099/jmm.0.000617&mimeType=html&fmt=ahah

References

  1. Medrano FJ, Montes-Cano M, Conde M, de La Horra C, Respaldiza N et al. Pneumocystis jirovecii in general population. Emerg Infect Dis 2005;11:245–250 [CrossRef][PubMed]
    [Google Scholar]
  2. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014;CD005590 [CrossRef][PubMed]
    [Google Scholar]
  3. Kofteridis DP, Valachis A, Velegraki M, Antoniou M, Christofaki M et al. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients. J Infect Chemother 2014;20:412–416 [CrossRef][PubMed]
    [Google Scholar]
  4. Dockrell DH, Breen R, Lipman M, Miller RF. 3 Pulmonary opportunistic infections. HIV Med 2011;12:25–42 [CrossRef]
    [Google Scholar]
  5. Maertens J, Cesaro S, Maschmeyer G, Einsele H, Donnelly JP et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother 2016;71:2397–2404 [CrossRef][PubMed]
    [Google Scholar]
  6. Coyle PV, Mccaughey C, Nager A, Mckenna J, O'Neill H et al. Rising incidence of Pneumocystis jirovecii pneumonia suggests iatrogenic exposure of immune-compromised patients may be becoming a significant problem. J Med Microbiol 2012;61:1009–1015 [CrossRef][PubMed]
    [Google Scholar]
  7. Long MD, Farraye FA, Okafor P. Increased risk of Pneumocystis Jiroveci pneumonia among patients with inflammatory bowel disease. 2014;191–13
  8. Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 2014;20:1490–1497 [CrossRef][PubMed]
    [Google Scholar]
  9. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012;25:297–317 [CrossRef][PubMed]
    [Google Scholar]
  10. Sokulska M, Kicia M, Wesołowska M, Hendrich AB. Pneumocystis jirovecii–from a commensal to pathogen: clinical and diagnostic review. Parasitol Res 2015;114:3577–3585 [CrossRef][PubMed]
    [Google Scholar]
  11. Tasaka S, Kobayashi S, Yagi K, Asami T, Namkoong H et al. Serum (1 → 3) β-d-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother 2014;20:678–681 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000617
Loading
/content/journal/jmm/10.1099/jmm.0.000617
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error